Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
MLYS compared with SPRY: revenue, margins and what each company keeps, and the suppliers and customers both name
MLYS
Mineralys Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
SPRY
ARS Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
MLYS
Mineralys Therapeutics, Inc.
vs
SPRY
ARS Pharmaceuticals, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
MLYS, solid
SPRY, dashed
Supply-chain overlap
Revenue flow
MLYS: latest quarter not drawable. SPRY: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only MLYS
1
—
Tanabe Pharma Corporation (Tanabe)
unlisted
supplier
Shared
0
No shared counterparties.
Only SPRY
18
—
ALK
unlisted
supplier
—
ALK U.S
unlisted
supplier
—
Recordati Ireland
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
—
Aegis Therapeutics
unlisted
supplier
14 more · SPRY chain
›
MLYS
Mineralys Therapeutics, Inc.
Change
18.14
▼
−14.62%
· post 18.15
Mkt cap
$1.6B
Revenue
—
Revenue
—
SPRY
ARS Pharmaceuticals, Inc.
Change
3.37
▼
−8.06%
· post 3.37
Closed
Oct 30 '26
Mkt cap
$336.1M
Revenue
$34M
Q2 FY26
Revenue
$84M
FY25
vs
Compare
Closed
Oct 30 '26
MLYS
Mineralys Therapeutics, Inc.
vs
SPRY
ARS Pharmaceuticals, Inc.
18.14
▼
−14.62%
post 18.15
Price
3.37
▼
−8.06%
post 3.37
$1.6B
Mkt cap
$336.1M
—
Revenue
$34M
Q2 FY26
—
Revenue
$84M
FY25
Change
Change
MLYS
18.14
▼
−14.62%
vs
SPRY
3.37
▼
−8.06%
Closed
Oct 30 '26